Press Releases

Press Releases

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


Yanghyun Foundation Donates KRW 37 Million to IVI to Support Vaccination Campaign in Earthquake-hit Nepal

2016-10-07 06:47
[caption id="attachment_14292" align="aligncenter" width="503"]1438663081397 Ms. Eunyoung Choi, the Chief Director of the Yanghyun Foundation and Chairwoman of Eusu Holdings, delivers a 37 million-won donation to Dr. Jerome Kim, Director General of IVI, to support a cholera vaccination campaign for Nepalese people at Eusu Holdings building in Seoul on August 4.[/caption]

  • IVI and the Yanghyun Foundation held a donation delivery ceremony at the Eusu Holdings Building on August 4

  • The funds will be used to support a cholera vaccination campaign in Nepal, where two devastating earthquakes hit earlier this year and left many at risk for cholera

  • The foundation has contributed a cumulative total of about KRW 243 million to IVI over the past 8 years

SEOUL, REPUBLIC OF KOREA – The International Vaccine Institute (IVI), an international organization based in Seoul, announced today that the Yanghyun Foundation donated KRW 37 million to IVI to support the institute’s vaccination campaign in earthquake-hit Nepal, during a fund delivery ceremony held at the Eusu Holdings Building in Yeouido. The philanthropic foundation has supported IVI over the past eight years, contributing a cumulative total of approximately KRW 243 million.

The donation ceremony was attended by Ms. Eunyoung Choi the Chief Director of the Yanghyun Foundation / Chairwoman of Eusu Holdings and Dr. Jerome Kim, Director General of IVI.

The donated funds will be used to support a cholera vaccination campaign in Nuwakot District, Nepal, targeting high-risk rural areas that have been hardest hit by the earthquakes. The vaccinations aim to protect 9,000 people living under difficult conditions with limited access to clean water, sanitation and health care services as a result of the severe damage caused by the two earthquakes in April and May, respectively. IVI, with local health officials and other partners, is coordinating the vaccination campaign.

“We express our sincere gratitude to the Yanghyun Foundation for their continuous support,” said IVI Director General Dr. Jerome Kim. He added, “The devastating earthquakes that hit Nepal earlier this year have left countless Nepalese, including children, at risk for cholera and other infectious diseases. We strongly believe the foundation’s support can make a difference in people’s lives in Nepal, and with their help, we will continue our efforts to improve the health of people in developing countries, especially children.”

“We are honored to contribute to this meaningful campaign and to IVI’s humanitarian efforts. We hope our support can be helpful in alleviating the suffering and enhancing the health of the earthquake victims in Nepal.” said Ms. Eunyoung Choi, the Chief Director of the Yanghyun Foundation.

The Yanghyun Foundation has been a consistent supporter of IVI since 2008, and has regularly donated funds to support IVI in its endeavors to save lives in developing countries through its vaccine research. The foundation supported IVI last year with the launch of its ‘Kids Helping Kids (KiKi) Program,’ a program that educates children about public health and charity; and IVI’s International Photo Contest.

About IVI
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to discovering, developing and delivering new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research at its headquarters in Seoul, Republic of Korea and in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, as well as dengue fever. For more information, please visit

Media Contacts:

Public Awareness/Advocacy Officer, IVI

Tae-kyung Byun

+82 2 872 2801 (Ext. 159) / Mobile +82 11 9773 6071

Burson-Marsteller Korea Contact:

Ayoung Jang

Phone: +82-2-3782-6465

Mobile: +82-10-3596-2440


Nayoung Kim

Phone: +82-2-3782-6458

Mobile: +82-10-8967-1909